Cargando…

Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction

AIMS: Concomitant renin–angiotensin–aldosterone system blockade and natriuretic peptide system enhancement may provide unique therapeutic benefits to patients with heart failure and reduced ejection fraction (HFrEF). This study assessed the pharmacodynamics and pharmacokinetics of LCZ696 in patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kobalava, Zhanna, Kotovskaya, Yulia, Averkov, Oleg, Pavlikova, Elena, Moiseev, Valentine, Albrecht, Diego, Chandra, Priya, Ayalasomayajula, Surya, Prescott, Margaret F., Pal, Parasar, Langenickel, Thomas H., Jordaan, Pierre, Rajman, Iris
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5108443/ https://www.ncbi.nlm.nih.gov/pubmed/26990595 http://dx.doi.org/10.1111/1755-5922.12183

Ejemplares similares

The effect of LCZ696 (sacubitril/valsartan) on amyloid‐β concentrations in cerebrospinal fluid in healthy subjects
por: Langenickel, Thomas H., et al.
Publicado: (2016)

Single therapeutic and supratherapeutic doses of sacubitril/valsartan (LCZ696) do not affect cardiac repolarization
por: Langenickel, Thomas H., et al.
Publicado: (2016)

Evaluation of Pharmacokinetic and Pharmacodynamic Drug–Drug Interaction of Sacubitril/Valsartan (LCZ696) and Sildenafil in Patients With Mild‐to‐Moderate Hypertension
por: Hsiao, H‐L, et al.
Publicado: (2017)

Effect of the angiotensin receptor–neprilysin inhibitor sacubitril/valsartan on the pharmacokinetics and pharmacodynamics of a single dose of furosemide
por: Ayalasomayajula, Surya, et al.
Publicado: (2018)

Cardioprotective Effects of LCZ696 (Sacubitril/Valsartan) After Experimental Acute Myocardial Infarction
por: Ishii, Masanobu, et al.
Publicado: (2017)

Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF
por: Jhund, Pardeep S., et al.
Publicado: (2015)

LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure
por: Lefkowitz, Martin P
Publicado: (2015)

Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double‐blind, randomized comparison of two uptitration regimens
por: Senni, Michele, et al.
Publicado: (2016)

Prevention against renal damage in rats with subtotal nephrectomy by sacubitril/valsartan (LCZ696), a dual‐acting angiotensin receptor‐neprilysin inhibitor
por: Ushijima, Kentaro, et al.
Publicado: (2017)

Sacubitril/valsartan (LCZ696) reduces myocardial injury following myocardial infarction by inhibiting NLRP3-induced pyroptosis via the TAK1/JNK signaling pathway
por: Shen, Jianfen, et al.
Publicado: (2021)

LCZ696 ameliorates lipopolysaccharide-induced endothelial injury
por: Gao, Aihong, et al.
Publicado: (2021)

Sacubitril/valsartan (LCZ696) ameliorates hyperthyroid-induced cardiac hypertrophy in male rats through modulation of miR-377, let-7 b, autophagy, and fibrotic signaling pathways
por: Khamis, Tarek, et al.
Publicado: (2022)

Angiotensin II receptor Neprilysin inhibitor (LCZ696) compared to Valsartan attenuates Hepatotoxicity in STZ-induced hyperglycemic rats
por: Alqahtani, Faleh, et al.
Publicado: (2020)

Safety of the neprilysin/renin-angiotensin system inhibitor LCZ696
por: Li, Bo, et al.
Publicado: (2017)

LCZ696 ameliorates doxorubicin-induced cardiomyocyte toxicity in rats
por: Miyoshi, Toru, et al.
Publicado: (2022)

A Meta-Analysis on the Effect and Safety of LCZ696 in the Treatment of Hypertension
por: Zheng, Li, et al.
Publicado: (2021)

Effect of Sacubitril/Valsartan on Exercise-Induced Lipid Metabolism in Patients With Obesity and Hypertension
por: Engeli, Stefan, et al.
Publicado: (2018)

A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure
por: McMurray, John, et al.
Publicado: (2015)

PARADIGM-HF trial: will LCZ696 change the current treatment of systolic heart failure?
por: Kaplinsky, Edgardo
Publicado: (2015)

LCZ696, an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure and hypertension
por: Lefkowitz, Martin P
Publicado: (2011)

Effect and safety of LCZ696 in the treatment of hypertension: A meta-analysis of 9 RCT studies
por: Li, Qiongqiong, et al.
Publicado: (2019)

The protective effect of LCZ696 in coxsackievirus B3‐induced acute viral myocarditis mice
por: Jing, Xu, et al.
Publicado: (2022)

Sacubitril/Valsartan Conundrum
por: Somberg, John
Publicado: (2021)

LCZ696, a promising novel agent in treating hypertension (a meta-analysis of randomized controlled trials)
por: Ye, Liwen, et al.
Publicado: (2017)

LCZ696 Ameliorates Isoproterenol-Induced Acute Heart Failure in Rats by Activating the Nrf2 Signaling Pathway
por: Hou, Min, et al.
Publicado: (2022)

The angiotensin receptor and neprilysin inhibitor, LCZ696, in heart failure: A meta-analysis of randomized controlled trials
por: Chen, Yan, et al.
Publicado: (2022)

Validation of the integration of technology that measures additional “vascular” indices into an ambulatory blood pressure monitoring system
por: Kotovskaya, Yulia V, et al.
Publicado: (2014)

LCZ696 Therapy Reduces Ventricular Tachyarrhythmia Inducibility in a Myocardial Infarction-Induced Heart Failure Rat Model
por: Chang, Po-Cheng, et al.
Publicado: (2019)

LCZ696 Attenuated Doxorubicin-Induced Chronic Cardiomyopathy Through the TLR2-MyD88 Complex Formation
por: Ye, Shiju, et al.
Publicado: (2021)

The Antihypertensive Effects and Safety of LCZ696 in Patients with Hypertension: A Systemic Review and Meta-Analysis of Randomized Controlled Trials
por: Chua, Su-Kiat, et al.
Publicado: (2021)

Direct actions of dapagliflozin and interactions with LCZ696 and spironolactone on cardiac fibroblasts of patients with heart failure and reduced ejection fraction
por: Ortega‐Paz, Luis, et al.
Publicado: (2022)

Implication of low dose sacubitril/valsartan
por: Imamura, Teruhiko
Publicado: (2021)

Eligibility and Usage of Sacubitril/Valsartan in Korea
por: Kim, Jin-Jin, et al.
Publicado: (2019)

Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction
por: Ito, Sadayoshi, et al.
Publicado: (2015)

LCZ696 mitigates diabetic-induced nephropathy through inhibiting oxidative stress, NF-κB mediated inflammation and glomerulosclerosis in rats
por: Mohany, Mohamed, et al.
Publicado: (2020)

LCZ696 Ameliorates Oxidative Stress and Pressure Overload-Induced Pathological Cardiac Remodeling by Regulating the Sirt3/MnSOD Pathway
por: Peng, Shi, et al.
Publicado: (2020)

Lcz696 Alleviates Myocardial Fibrosis After Myocardial Infarction Through the sFRP-1/Wnt/β-Catenin Signaling Pathway
por: Liu, Jing, et al.
Publicado: (2021)

Effect of LCZ696, a dual angiotensin receptor neprilysin inhibitor, on isoproterenol-induced cardiac hypertrophy, fibrosis, and hemodynamic change in rats
por: Miyoshi, Toru, et al.
Publicado: (2019)

Insights into implementation of sacubitril/valsartan into clinical practice
por: Martens, Pieter, et al.
Publicado: (2018)

Sacubitril–valsartan in heart failure and multimorbidity patients
por: Rodil Fraile, Raquel, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4iind4iucaa28dutuq7fhe8rup